Phase 3 data for zasocitinib has shown rapid and durable skin clearance in plaque psoriasis. The treatment has demonstrated consistent and high rates of skin clearance across the body, including hard-to-treat areas. Results from the phase 3 studies have been reported, with details on the treatment's efficacy and administration, including its use as a once-daily oral medication.